Weight Management
Physician-supervised metabolic care using GLP-1 therapies where clinically appropriate.
$329/ month$199 to start, labs and evaluation included
Conditions and concerns
Metabolic weight management
Physician-supervised weight management with baseline metabolic labs, eligibility review and ongoing monitoring. GLP-1 therapy where clinically appropriate.
GLP-1 eligibility
GLP-1 therapy has defined eligibility criteria and clear contraindications. Learn what a provider checks before prescribing.
What a provider may prescribe
Semaglutide
Semaglutide is a glucagon-like peptide-1 receptor agonist. It acts on receptors involved in appetite regulatio…
Tirzepatide
Tirzepatide is a dual agonist acting at both GIP and GLP-1 receptors. It is available as an FDA-approved brand…
Metformin
Metformin is a biguanide that reduces hepatic glucose production and improves insulin sensitivity. It has one …
Weighing the options
Markers reviewed in this area
Every marker below has a reference page explaining what it measures and why it is tracked.
Questions people ask
How does semaglutide work?
Semaglutide is a GLP-1 receptor agonist. It acts on receptors involved in appetite regulation and slows gastric emptying, which affects how full you feel and for how long. It is given as a once-weekly injection, started low and titrated upward over several weeks to manage tolerability. Whether it is appropriate depends on eligibility criteria and your medical history.
Am I eligible for GLP-1 therapy?
Eligibility generally rests on BMI thresholds, with a lower threshold applying where weight-related comorbidities are present. There are also absolute contraindications: a personal or family history of medullary thyroid carcinoma or MEN2 rules the class out entirely, and a history of pancreatitis requires careful consideration. A provider determines eligibility after reviewing your intake and laboratory results, and not everyone qualifies.
What side effects does semaglutide have?
Gastrointestinal effects are the most commonly reported — nausea, constipation, diarrhoea and reflux — and are most pronounced during dose escalation. This is why titration is gradual. The class carries a boxed warning regarding thyroid C-cell tumours based on rodent studies. Pancreatitis and gallbladder disease are less common but require prompt attention. Report anything unexpected to your provider rather than waiting for a scheduled review.
What happens if I stop GLP-1 therapy?
Appetite regulation generally returns toward its previous state once the medication is cleared, and weight regain is commonly observed. This is a recognised feature of the therapy rather than a failure, and it is why providers discuss the longer-term plan at the outset rather than treating it as a short course. Any decision to stop should be made with your provider.
Do you offer compounded semaglutide or tirzepatide?
Not as a general offering. The FDA declared the semaglutide and tirzepatide shortages resolved, which ended the basis on which pharmacies could compound copies of them, and enforcement discretion for outsourcing facilities ended in March 2025. What remains available is the FDA-approved branded product, and genuine patient-specific compounding only where a prescriber documents a clinical need the approved product cannot meet. Any provider offering compounded copies as a routine low-cost alternative is operating outside that framework.
Is metformin a weight-loss medication?
Metformin is not approved for weight management. It is a metabolic medication used primarily in type 2 diabetes and insulin resistance, and providers sometimes use it in metabolic care where the laboratory picture supports it. Any effect on weight is modest compared with GLP-1 therapy. Whether it has a role for you depends on your metabolic markers.